Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NPSP NPS Pharmaceutical -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (53)	12/23/1999 12:53:00 PM
From: biowa	Read Replies (1) \| Respond to of 363

Walter, I have to run out and do some last minute shopping (as usual!) but I'll try to post some of his key observations in the next few days. That would be great. Good luck with the crowds. Have a super holiday! The same to you and yours, biowa

To: WTDEC who wrote (53)	12/23/1999 1:11:00 PM
From: biowa	Respond to of 363

Walter, I've just been updated on my earlier list in terms of what NPS has publicly announced: HPT (secondary & primary) PII results and PIII start Osteoprosis ALX 1-11 PIII trial start (announced for 2Q00) GI (short bowel syndrome) ALX 0600 pilot PII results and PIIb start In terms of partnering (and thus clinical progress), the public statement is for licensing of one or more NPS compounds, which supports the earlier: Epilepsy (& perhaps bipolar) NPS 1776 additional PI results, partner and perhaps PII start Stroke (& perhaps trauma) NPS 1506 perhaps partner and PII start? AND an additional item: Schizophrenia selection of a clinical candidate in the GlyT-1 program with Janssen biowa